Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1355-1361

  Salem, Ahmed Hamed ^a,b   Agarwal, Suresh K ^a   Dunbar, Martin ^a   Nuthalapati, Silpa ^a   Chien, David ^a   Freise, Kevin J ^a   Wong, Shekman L ^a  

^a ABBVIE INC   (United States)

^b African Union Organization St Abbassia   (Egypt)

Author keywords

BCL 2; bioavailability; CLL; fat; food effect; NHL; pharmacokinetics; venetoclax

Indexed keywords

VENETOCLAX;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FAT CONTENT; FATIGUE; FEMALE; FILM COATING; HALF LIFE TIME; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; INSECT BITE; LACERATION; LIPID DIET; LOW FAT DIET; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OPEN STUDY; ORAL CLEARANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN IRRITATION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOLUME OF DISTRIBUTION; VOMITING;

EID: 84990249282     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.741     Document Type: Article

References (20)

1. Akl H, Vervloessem T, Kiviluoto S, et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta. 2014;1843(10):2240–2252.
2. Roberts AW, Davids MS, PageL JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
3. Ma S, Brander DM, Seymour JF, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126:830.
4. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discovery 2016. Submitted.
5. Moreau P, Chanan-Khan A, Roberts AW, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2105;126:3038.
6. De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood. 2015;126:255.
7. DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ 65 years and not eligible for standard induction therapy. Blood. 2015;126:327.
8. VenclextaTM(venetoclax tablets) prescribing information. North Chicago, IL, and South San Francisco, CA: AbbVie Inc. and Genentech USA; 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf. Accessed May 6, 2016.
9. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016; doi:10.1002/jcph.730.
10. US Department of Health and Human Services, FDA and CDER. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. December 2002. http://www.fda.gov/downloads/guidances/ucm126833.pdf. Accessed January 12, 2016.
11. Lee, I.D., Amidon, G. Pharmacokinetic Analysis: A Practical Approach. Taylor & Francis; 1996. https://books.google.com/books?id=ZR6kVXSRW7wClpg=PP1dq=Pharmacokinetic%20Analysis%3A%20A%20Practical%20Approachpg=PP1#v=onepageq=Pharmacokinetic%20Analysis:%20A%20Practical%20Approachf=false. Accessed January 26, 2016.
12. Choo EF, Boggs J, Zhu C, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos. 2014;42(2):207–212.
13. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702–716.
14. Porter CJ, Charman SA, Humberstone AJ, Charman WN. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J Pharm Sci. 1996;85(4):357–361.
15. Khoo SM, Edwards GA, Porter CJ, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90(10):1599–1607.
16. Xiong H, Pradhan RS, Nada A, et al. Studying navitoclax, a targeted anticancer drug, in healthy volunteers–ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014;34(7):3739–3746.
17. Freise KJ, Jones AK, Eckert D, et al. Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; April 16–20, 2016; New Orleans, Louisiana: AACR; Cancer Res. 2016:Abstract 3907.
18. Gerecitano JF, Roberts AW, Seymour JF, et al. A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126:254.
19. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: Results of the pivotal international phase 2 study. Blood. 2015;126(23):LBA–6.
20. Jones J, Mato AR, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. Blood. 2015;126(23):715.